five

Dataset from A Phase IIIB, Multi-center, Open Label Follow-up Study to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered Concomitantly With DMARDs in Patients With Active Rheumatoid Arthritis Who Participated in C87076.

收藏
NIAID Data Ecosystem2026-05-02 收录
下载链接:
https://doi.org/10.25934/PR00007915
下载链接
链接失效反馈
官方服务:
资源简介:
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
创建时间:
2024-11-26
二维码
社区交流群
二维码
科研交流群
商业服务